Donepezil/Solifenacin

多奈哌齐/索利那新

Report date: 2022/09/06 14:06:21

Base Information

Drug NameDonepezil/Solifenacin
Drug Alias Name多奈哌齐索利那新Donepezil+SolifenacinSolifenacin+Donepezil索利那新+多奈哌齐Solifenacin/Donepezil +[11] 
ClassificationSmall molecules
Mechanisms of ActionAcetylcholinesterase inhibitorsMuscarinic acetylcholine receptor M3 antagonists
TargetsAcetylcholinesteraseMuscarinic acetylcholine receptor M3
Therapy Area/IndicationsUrologic DiseasesAlzheimer DiseaseDementia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesEgypt
CombinationsYes Donepezil HydrochlorideSolifenacin Succinate
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCipla IncAllergan Plc
China Registration ClassN/A

Develop Information

Active CompaniesMansoura University
Inactive CompaniesChase Pharmaceuticals Corporation, An Affiliate Of Allergan Plc
Active IndicationsUrologic Diseases
Inactive IndicationsAlzheimer DiseaseDementia

Other Information

ATC CodeN/A
Related LinksN/A